Critical Outcome Technologies Receives Orphan Drug Designation For COTI-2

Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE:COT)(OTCQB:COTQF), the bioinformatics and accelerated drug discovery company, announced today that the U.S. Food and Drug Administration (FDA) has granted COTI-2 an Orphan Drug Designation for the treatment of ovarian cancer.
http://bit.ly/1yebroJ